Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-224 in Patients With Advanced Cancer

Exclusion Criteria

• •Prior cancer therapies must have completed at least 14 days or 5 half-lives (whichever is longer) prior to first dose of AMP-224
• •Prior treatment with an anti-PD1 antibody therapy
• •Known antibody response against prior antibody therapy or fusion protein therapeutics
• •Major surgery within 4 weeks prior to first dose of AMP-224
• •Prior allogeneic or autologous bone marrow or organ transplantation
• •Known and/or a history or evidence of autoimmune disease except vitiligo, resolved childhood asthma and stable hypothyroidism
• •Received an immunomodulatory drug within 2 weeks of first dose of AMP-224
• •Active infections requiring antibiotics, physician monitoring, or recurrent fevers \>100.4 degrees fahrenheit associated with a clinical diagnosis of active infection
• •Patients with cirrhosis
• •Clinically significant cardiac or electrocardiogram abnormalities
• •History or evidence of HIV
• •Active viral disease (except when the viral infection is associated with the malignancy)
• •Regular use of illicit drugs or a recent history of substance abuse
• •Pregnant or breastfeeding women